一个VLP疫苗平台,包括乙型肝炎病毒的核心蛋白质,具有N终端抗原捕获
Kaniz Fatema1, Joseph S Snowden1, Alexander Watson1
1Astbury Centre for Structural Molecular Biology, School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds LS2 9JT, United Kingdom.
International journal of biological macromolecules
|February 17, 2025
概括
一个新的纳米粒子疫苗平台N-VelcroVax有效地结合病毒抗原. 该平台使用乙型肝炎病毒核心蛋白构建,有望迅速开发针对新兴疾病的疫苗.
科学领域:
- 疫苗学 疫苗学 疫苗学
- 结构生物学是结构生物学.
- 生物技术是生物技术.
背景情况:
- 新出现的传染病凸显了快速开发疫苗的必要性.
- 纳米粒子支架为疫苗设计提供了一个有希望的方法.
- 之前的工作引入了VelcroVax,一种使用协同HBc蛋白的VLP支架.
研究的目的:
- 开发和描述一个替代的VLP疫苗平台,N-VelcroVax.
- 评估N-VelcroVax结合目标抗原的能力.
- 评估N-VelcroVax作为下一代疫苗支架.
主要方法:
- 使用单体HBc蛋白与N端 Affimer插入构建N-VelcroVax.
- 在大肠杆菌中N-VelcroVax VLP的表达.
- 使用SUMO标记的Junín病毒糖蛋白 (gp1) 的结合性测试.
- 结构和血清学分析,包括 Cryo-EM.
主要成果:
- 在大肠杆菌中成功表达了N-VelcroVax VLP.
- N-VelcroVax有效地结合了SUMO标记的朱宁病毒gp1.1.
- 结冷EM证实了N-VelcroVax复合体中的affimer密度和目标抗原捕获.
结论:
- N-VelcroVax代表了一个可行的替代VLP疫苗平台.
- 该平台展示了高效的抗原结合能力.
- N-VelcroVax显示出作为未来疫苗开发的多功能支架的潜力.
相关概念视频
01:33Enzyme-Linked Immunosorbent Assay
12.4K
In 1971, Peter Perlman and Eva Engvall developed an Enzyme-linked immunosorbent assay (ELISA or EIA). ELISA differs from western blot in that the assays are conducted in microtiter plates or in vivo rather than on an absorbent membrane.
There are many different types of ELISAs, but they all involve an antibody molecule whose constant region binds an enzyme, leaving the variable region free to bind its specific antigen. Enzyme-substrate reaction allows the antigen to be visualized or...
There are many different types of ELISAs, but they all involve an antibody molecule whose constant region binds an enzyme, leaving the variable region free to bind its specific antigen. Enzyme-substrate reaction allows the antigen to be visualized or...
12.4K
01:51Vaccinations
43.8K
Overview
43.8K
01:22Antigen Presenting Cells
1.7K
The immune system is a complex network of cells and molecules that protects the body from foreign invaders. T cells, a type of white blood cell, play a crucial role in this process. They recognize and attack foreign substances, such as pathogens, that enter the body.
T cells require the help of antigen-presenting cells (APCs), which process foreign antigens into smaller fragments that can be recognized by T cells. These APCs are highly specialized cells that efficiently internalize antigens...
T cells require the help of antigen-presenting cells (APCs), which process foreign antigens into smaller fragments that can be recognized by T cells. These APCs are highly specialized cells that efficiently internalize antigens...
1.7K
01:31Hybridoma Technology
14.0K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
14.0K